Stock overview
Eli Lilly & Co.
Explore the company, reported ownership, price history, and available source evidence.
Eli Lilly develops medicines for diabetes, obesity, oncology, immunology, and neuroscience.
- Last close
- $1382.75
- · LLY
- Tracked holders
- 7 funds
- Latest available 13F per fund
LLY · USD
Price
Close · Nov 18, 2026
- Range low
- $851.21
- Range high
- $1,443.50
- Observations
- 252
- Session date
- Nov 18, 2026
Nov 18, 2025–Nov 18, 2026. Regular market hours only. Historical prices are unadjusted; splits and other corporate actions can affect comparisons.
Investor Popularity
Rows are narrowed by movement, fund type, and position size.
| Fund | Move | Value | Weight |
|---|---|---|---|
| Polen Capital Management largest tracked holder Q3 2026 · filed Nov 13, 2026 · SEC filing | −45% 26'Q3 | $427,354,307 | 4.64% |
| ARK Investment Management position history Q3 2026 · filed Nov 13, 2026 · SEC filing | +40% 26'Q3 | $124,776,742 | 0.72% |
| Gotham Asset Management position history Q3 2026 · filed Nov 16, 2026 · SEC filing | +33% 26'Q3 | $33,917,486 | 0.07% |
| Tudor Investment Corp position history Q3 2026 · filed Nov 16, 2026 · SEC filing | −77% 26'Q3 | $8,385,359 | 0.01% |
|
Thrive Capital
position history
Q2 2026
· filed Aug 14, 2026
· SEC filing 1 SEC filing 2 |
+11% 26'Q2 | $5,224,135 | 0.12% |
| Duquesne Family Office position history Q3 2026 · filed Nov 16, 2026 · SEC filing | −69% 26'Q3 | $4,397,000 | 0.1% |
| Renaissance Technologies position history Q3 2026 · filed Nov 12, 2026 · SEC filing | −98% 26'Q3 | $504,103 | 0% |
SEC Forms 4/5
Insiders
Financials
Official-source analysis
AI Earnings Report
No published AI Earnings Report yet
We publish a cited AI Earnings Report after an eligible official earnings filing is accepted and passes validation.
Options market